Related Experiment Videos
Three-week hepatitis B vaccination provides protective immunity
B Marchou1, N Picot, P Chavanet
1Service des Maladies Infectieuses et Tropicals, Hôpital Purpan, Toulouse, France.
Vaccine
|November 1, 1993
Summary
A 3-week hepatitis B (HB) vaccination schedule using GenHevac B demonstrated early and lasting protective immunity in young adults. Schedule B, with doses on days 0, 10, and 21, showed higher seroprotection rates and antibody titers.
Area of Science:
- Immunology
- Vaccinology
- Public Health
Background:
- Hepatitis B (HB) remains a significant global health concern.
- Establishing protective immunity rapidly is crucial for disease prevention.
- Standard HB vaccination schedules may not always provide immediate protection.
Purpose of the Study:
- To evaluate the efficacy of a compressed 3-week hepatitis B vaccination regimen.
- To compare two different accelerated schedules for HB vaccine administration.
- To assess the speed and durability of protective immunity induced by accelerated HB vaccination.
Main Methods:
- 89 healthy, unvaccinated young adults received three doses of 20 micrograms HBs antigen (GenHevac B).
- Participants were randomized into Schedule A (doses on days 0, 0, 21) or Schedule B (doses on days 0, 10, 21).
- Seroprotection rates and anti-HBs geometric mean titers were measured at various time points.
Main Results:
- At day 21, seroprotection rates were 23% (Schedule A) and 40% (Schedule B).
- By day 82, rates increased to 77% (A) and 91% (B), with significantly higher titers in Schedule B.
- One year post-vaccination, Schedule B maintained 90% seroprotection.
Conclusions:
- A 3-week hepatitis B vaccination schedule with GenHevac B can achieve early protective immunity.
- Schedule B (doses on days 0, 10, 21) demonstrated superior immunogenicity and faster seroprotection.
- This accelerated regimen offers a viable option for rapid and sustained protection against Hepatitis B.